Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study

American Journal of Ophthalmology

Volumn 168, Issue , 2016, Pages 250-259

  Medeiros, Felipe A ^a   Martin, Keith R ^b   Peace, James ^c   Scassellati Sforzolini, Baldo ^d   Vittitow, Jason L ^d   Weinreb, Robert N ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c United Medical Research   (United States)

^d BAUSCH AND LOMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROSTENE BUNOD; TIMOLOL MALEATE; ANTIHYPERTENSIVE AGENT; BOL 303259-X; EYE DROPS; PROSTAGLANDIN F; TIMOLOL;

ABNORMAL SENSATION; ADULT; AGED; ANALYSIS OF COVARIANCE; APPLICATION SITE PAIN; ARTICLE; ASTHENOPIA; BLURRED VISION; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; DRY EYE; DYSGEUSIA; DYSPNEA; EUROPEAN UNION; EVENING DOSAGE; EYE IRRITATION; EYE PAIN; FEMALE; FOREIGN BODY SENSATION; HAIR DISEASE; HEADACHE; HUMAN; INSOMNIA; INSTILLATION SITE PAIN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MADAROSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PERIOCULAR RASH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT DISEASE; SOMNOLENCE; THORAX PAIN; TREATMENT DURATION; UNITED STATES; ANALYSIS OF VARIANCE; CLINICAL TRIAL; GLAUCOMA, OPEN-ANGLE; MIDDLE AGED; OCULAR HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY; VISUAL ACUITY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL; VISUAL ACUITY; YOUNG ADULT;

EID: 84979072533     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2016.05.012     Document Type: Article

References (40)

1. 1 Krauss, A.H., Impagnatiello, F., Toris, C.B., et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp Eye Res 93:3 (2011), 250–255.
2. 2 Nathanson, J.A., Nitrovasodilators as a new class of ocular hypotensive agents. J Pharmacol Exp Ther 260:3 (1992), 956–965.
3. 3 Kotikoski, H., Alajuuma, P., Moilanen, E., et al. Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP. J Ocul Pharmacol Ther 18:1 (2002), 11–23.
4. 4 Schuman, J.S., Erickson, K., Nathanson, J.A., Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys. Exp Eye Res 589:1 (1994), 99–105.
5. 5 Heyne, G.W., Kiland, J.A., Kaufman, P.L., Gabelt, B.T., Effect of nitric oxide on anterior segment physiology in monkeys. Invest Ophthalmol Vis Sci 54:7 (2013), 5103–5110.
6. 6 Ota, T., Aihara, M., Saeki, T., Narumiya, S., Araie, M., The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol 91:5 (2007), 673–676.
7. 7 Aptel, F., Cucherat, M., Denis, P., Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 17:8 (2008), 667–673.
8. 8 Rouland, J.F., Traverso, C.E., Stalmans, I., et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol 97:2 (2013), 196–200.
9. 9 Wizemann, A.J., Wizemann, V., Organic nitrate therapy in glaucoma. Am J Ophthalmol 90:1 (1980), 106–109.
10. 10 Diestelhorst, M., Hinzpeter, B., Krieglstein, G.K., The effect of isosorbide-mononitrate eye drops on the human intraocular pressure and aqueous humor dynamics. Int Ophthalmol 15:4 (1991), 259–262.
11. 11 Garway-Heath, D.F., Crabb, D.P., Bunce, C., et al. Latanoprost for open-angle glaucoma (UKGTS): a randomized, multicenter, placebo-controlled trial. Lancet 385:9975 (2015), 1295–1304.
12. 12 Lei, Y., Zhang, X., Song, M., et al. Aqueous humor outflow physiology in NOS3 knockout mice. Invest Ophthalmol Vis Sci 56:8 (2015), 4891–4898.
13. 13 Chang, J.Y., Stamer, W.D., Bertrand, J., et al. Role of nitric oxide in murine conventional outflow physiology. Am J Physiol Cell Physiol 309:4 (2015), C205–C214.
14. 14 Xalatan [package insert], 2014, Pfizer Inc, New York, NY.
15. 15 Lütjen-Drecoll, E., Tamm, E., Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2a. Exp Eye Res 47:5 (1988), 761–769.
16. 16 Gabelt, B.T., Kaufman, P.L., Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 49:3 (1989), 389–402.
17. 17 Nilsson, S.F., Samuelsson, M., Bill, A., Stjernschantz, J., Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res 48:5 (1989), 707–716.
18. 18 Toris, C.B., Camras, C.B., Yablonski, M.E., Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 100:9 (1993), 1297–1304.
19. 19 Lindsey, J.D., Kashiwagi, K., Kashiwagi, F., Weinreb, R.N., Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci 38:11 (1997), 2214–2223.
20. 20 Schachtschabel, U., Lindsey, J.D., Weinreb, R.N., The mechanism of action of prostaglandins in uveoscleral outflow. Curr Opin Ophthalmol 11:2 (2000), 112–115.
21. 21 Gaton, D.D., Sagara, T., Lindsey, J.D., Gabelt, B.T., Kaufman, P.L., Weinreb, R.N., Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol 119:8 (2001), 1165–1170.
22. 22 Richter, M., Krauss, A.H., Woodward, D.F., Lütjen-Drecoll, E., Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 44:10 (2003), 4419–4426.
23. 23 Wiederholt, M., Sturm, A., Lepple-Wienhues, A., Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci 35:5 (1994), 2515–2520.
24. 24 Schneemann, A., Dijkstra, B.G., van den Berg, T.J., Kamphuis, W., Hoyng, P.F., Nitric oxide/guanylate cyclase pathways and flow in anterior segment perfusion. Graefes Arch Clin Exp Ophthalmol 240:11 (2002), 936–941.
25. 25 Kotikoski, H., Vapaatalo, H., Oksala, O., Nitric oxide and cyclic GMP enhance aqueous humor outflow facility in rabbits. Curr Eye Res 26 (2003), 119–123.
26. 26 Dismuke, W.M., Liang, J., Overby, D.R., Stamer, W.D., Concentration-related effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility. Exp Eye Res 120 (2014), 28–35.
27. 27 Cavet, M.E., Vittitow, J.L., Impagnatiello, F., Ongini, E., Bastia, E., Nitric oxide (NO): an emerging target for the treatment of glaucoma. Invest Ophthalmol Vis Sci 55 (2014), 5005–5015.
28. 28 Cavet, M.E., Vollmer, T.R., Harrington, K.L., VanDerMeid, K., Richardson, M.E., Regulation of endothelin-1– induced trabecular meshwork cell contractility by latanoprostene bunod. Invest Ophthalmol Vis Sci 56 (2015), 4108–4116.
29. 29 Weinreb, R.N., Ong, T., Scassellati Sforzolini, B., et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 99:6 (2015), 738–745.
30. 30 Weinreb, R.N., Scassellati Sforzolini, B., Vittitow, J., Liebmann, J., Latanoprostene bunod 0.024% vs timolol maleate 0.5% in the treatment of open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology 123:5 (2016), 965–973.
31. 31 Higginbotham, E.J., Olander, K.W., Kim, E.E., et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol 128:2 (2010), 165–172.
32. 32 Feldman, R.M., Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 19:1 (2003), 23–25.
33. 33 Zhang, W.Y., Po, A.L., Dua, H.S., Azuara-Blanco, A., Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 85:8 (2001), 983–990.
34. 34 Alm, A., Camras, C.B., Watson, P.G., Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 41:2 (1997), S105–S110.
35. 35 Kass, M.A., Heuer, D.K., Higginbotham, E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol 120:6 (2002), 701–703.
36. 36 Heijl, A., Leske, M.C., Bengtsson, B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120:10 (2002), 1268–1279.
37. 37 Leske, M.C., Heijl, A., Hussein, M., et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 121:1 (2003), 48–56.
38. 38 Chauhan, B.C., Mikelberg, F.S., Balaszi, A.G., et al. Canadian Glaucoma Study Group. Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 126:8 (2008), 1030–1036.
39. 39 Heijl, A., Glaucoma treatment: by the highest level of evidence. Lancet 385:9975 (2015), 1264–1266.
40. 40 Orme, M., Collins, S., Dakin, H., Kelly, S., Loftus, J., Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Curr Med Res Opin 26:3 (2010), 511–528.